Trial Profile
A randomized, double-blind, multicentre, placebo-controlled study to evaluate the efficacy, dose-response and safety of tesaglitazar therapy in Japanese subjects with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tesaglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 08 Aug 2006 Status change
- 29 Mar 2006 New trial record.